Form 4: Insider Ownership Shift at ProMIS Neurosciences

Michael S. Gordon reports a significant reduction in his beneficial ownership of ProMIS Neurosciences shares due to an asset assignment and management change.

Summary

• Michael S. Gordon, a reporting person for ProMIS Neurosciences Inc. (PMN), filed a Form 4 to report changes in his beneficial ownership.
• On March 13, 2025, the ownership of 48,333 common shares held by Title 19 Acies was assigned to Skye Peak Partners LLC (SPP), effective January 1, 2025.
• Following this assignment, Michael S. Gordon no longer has investment control or pecuniary interest in these 48,333 shares.
• His role as sole manager of Title 19 Acies was transferred to Emmett Gordon and Michael Youniss.
• Michael S. Gordon retains beneficial ownership of 2,435,029 common shares through Title 19 Promis, where he remains the sole manager.
• As of August 14, 2025, his total beneficial ownership in ProMIS Neurosciences Inc. has dropped below the 10% threshold, based on 51,806,497 common shares outstanding reported in the Issuer's August 13, 2025 Form 10-Q.
• At the time the Form 4 was due, Michael S. Gordon's ownership was above 10%.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to a significant insider relinquishing control over a portion of shares and dropping below a key ownership threshold, coupled with the explicit mention of a late filing. While not a direct sale by the insider, it represents a reduction in direct influence.

Negatives

• Michael S. Gordon, a significant beneficial owner, has relinquished control and pecuniary interest over 48,333 common shares of ProMIS Neurosciences Inc.
• His overall beneficial ownership has dropped below the 10% threshold.
• The Form 4 was filed late, indicating a delay in reporting the transaction.

Risks

• Potential negative market perception due to a significant insider reducing their beneficial ownership and control.
• Implications of a late Form 4 filing, which could suggest compliance issues or a lack of timely disclosure.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The Issuer's Form 10-Q filed on August 13, 2025 provides that as of such date, the Issuer had 51,806,497 Common Shares outstanding.
• Based on this number and other shares included in the denominator of the calculation of the Reporting Person's ownership, the Reporting Person's ownership has dropped below 10% as of the date of filing this late Form 4.
• However, based on the publicly available number of outstanding shares reported prior to when this Form 4 was due, the Reporting Person held more than 10% at such time the Form 4 was due.

Industry Context

This Form 4 filing is specific to an individual insider's ownership changes and does not directly relate to broader industry trends or competitive dynamics.

Management Changes

Stakeholder Impact

• Shareholders may perceive the reduction in a significant insider's beneficial ownership and control as a negative signal, potentially impacting investor confidence.
• The late filing could raise questions among regulatory bodies regarding compliance with reporting requirements.

Key Dates

Recommendation

The filing indicates a reduction in beneficial ownership and control by a significant insider, Michael S. Gordon, due to an assignment of an investment entity. While not a direct sale by the insider, the relinquishment of control over a portion of shares and the drop below the 10% ownership threshold, coupled with the late filing, could be perceived negatively by the market. However, the insider retains a substantial holding through another entity. Investors should monitor future filings for any direct sales or further changes in beneficial ownership before making a definitive buy or sell decision.

Keywords

ProMIS Neurosciences, PMN, Form 4, insider ownership, beneficial ownership, Michael S. Gordon, equity, shares, ownership change, SEC filing